| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.095 | 0.002 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.003 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.006 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.007 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.32 | 0.01 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.02 |